证券日报网讯 10月14日晚间，博济医药发布公告称，公司于2025年8月25日召开第五届董事会第十六次 会议以及于2025年9月12日召开2025年第一次临时股东大会，审议通过了《关于变更公司注册资本及修 订的议案》，同意公司变更注册资本，并根据相关规定及公司实际情况对《公司章程》中相关内容进行 修订。近日，公司完成了上述事项的工商变更登记及备案手续，取得了广州市市场监督管理局换发的 《营业执照》。 （编辑 任世碧） ...

证券代码：300404 证券简称：博济医药 公告编号：2025-077 博济医药科技股份有限公司 关于公司完成工商变更登记及备案的公告 统一社会信用代码：91440101743555883K 名称：博济医药科技股份有限公司 类型：其他股份有限公司（上市） 住所：广州黄埔区科学城南翔一路 62 号（二、三、四、五）栋 法定代表人：王廷春 注册资本：叁亿捌仟伍佰伍拾伍万陆仟零柒拾捌元（人民币） 成立日期：2002 年 9 月 29 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日召开 第五届董事会第十六次会议以及于 2025 年 9 月 12 日召开 2025 年第一次临时股 东大会，审议通过了《关于变更公司注册资本及修订<公司章程>的议案》，同意 公司变更注册资本，并根据相关规定及公司实际情况对《公司章程》中相关内容 进行修订。具体内容详见公司于 2025 年 8 月 27 日、2025 年 9 月 13 日披露在巨 潮资讯网（www.cninfo.com.cn）上的相关公告。 近 ...

Core Insights - The article discusses the rapid development and investment in the biomanufacturing sector in China, highlighting various projects and initiatives aimed at establishing mid-test platforms across multiple regions [5][6][12]. Investment and Project Developments - In Chongqing, a total of 32 projects with an investment of 14.53 billion yuan were signed, focusing on biomanufacturing, biomedicine, and other high-tech industries [5]. - The Chongqing Biomanufacturing Industry Pilot Platform aims to create a national-level mid-test platform for biomanufacturing, emphasizing intelligent biological fermentation and related technologies [6]. - The platform is part of a broader initiative that includes 1,252 key projects with a total investment of approximately 3.2 trillion yuan planned for 2025 [6]. Regional Initiatives - Changde Economic Development Zone is also advancing its synthetic biomanufacturing mid-test conversion platform, with significant construction progress reported [7][8]. - The Changde platform has a total investment of 169 million yuan and will feature multiple mid-test production lines to cater to various scales and types of biomanufacturing [8]. National Support and Policy Framework - Multiple provinces, including Guangdong, Shanghai, and Sichuan, are actively supporting the establishment of mid-test platforms, with specific funding and policy frameworks in place [10][11][12]. - The Ministry of Industry and Information Technology and the National Development and Reform Commission have set a goal to cultivate over 20 mid-test capability construction platforms by 2027, aiming to serve more than 200 enterprises [12].

Core Viewpoint - Shanghai Xiaofang Pharmaceutical Co., Ltd. has signed a technical entrustment contract with Boji Pharmaceutical Technology Co., Ltd. to assist in the clinical research and registration of the new traditional Chinese medicine "Compound Cèbǎi Tincture" for hair loss treatment, marking a significant step in the company's innovation drug strategy [2][12]. Group 1: Transaction Overview - The transaction does not constitute a major asset restructuring as defined by the relevant regulations and does not involve related party transactions [2]. - The collaboration aims to complete the clinical trials and market registration of the new drug, with no significant impact on the company's operating results for the current year [3][12]. Group 2: Partner Information - Boji Pharmaceutical, established in 2002 and listed on the Shenzhen Stock Exchange in 2015, specializes in providing comprehensive outsourcing services for drug and medical device development [4]. - The company has a registered capital of 381.99 million RMB and has a strong track record in traditional Chinese medicine research and development [4]. Group 3: Project Details - The project involves the development of the traditional Chinese medicine "Compound Cèbǎi Tincture" through a commissioned development approach [5]. - Boji Pharmaceutical is responsible for designing and executing the research plans, conducting clinical trial monitoring, and assisting in the registration application [7]. Group 4: Contractual Terms - The intellectual property generated from the project will belong to Shanghai Xiaofang Pharmaceutical, including clinical trial data and research reports [6]. - The contract will be effective upon signing and will remain valid until the new drug application (NDA) is approved [9]. Group 5: Impact on the Company - The collaboration is expected to leverage the strengths of both companies, enhancing the efficiency and success rate of the product's development, thereby laying a solid foundation for future applications and market entry [12].

Core Viewpoint - The collaboration between Xiao Fang Pharmaceutical and Boji Pharmaceutical marks a significant step in the development of innovative drugs, particularly in the clinical research and registration of a new traditional Chinese medicine product [1] Group 1: Partnership Details - Xiao Fang Pharmaceutical has signed a "Technical Entrustment (Development) Contract" with Boji Pharmaceutical to assist in the clinical research and registration of a Class 1 traditional Chinese medicine compound [1] - This partnership is based on a shared strategic development vision, indicating a strong alliance between the two companies [1] Group 2: Strategic Implications - The collaboration is expected to leverage Boji Pharmaceutical's strengths in research and development, technical expertise, and clinical resources, enhancing the efficiency and success rate of the product's development [1] - The partnership aims to establish a solid foundation for the subsequent application and market launch of the product [1]

Core Viewpoint - The company, Xiao Fang Pharmaceutical, has signed a technical entrustment contract with Boji Pharmaceutical to assist in the clinical research and registration of a new traditional Chinese medicine, Compound Cypraea Tincture, which is classified as a Class 1 new drug [1] Group 1 - The collaboration aims to facilitate the completion of clinical trials and the subsequent market launch of the new drug [1] - This transaction does not constitute a major asset restructuring or a related party transaction [1] - The agreement is not expected to have a significant impact on the company's operating results for the current fiscal year [1]

锚定"四新"赛道 产业集聚效应凸显 金秋九月，北国春城长春迎来一场聚焦产业升级的盛会。9月19日至20日，由中国投资协会、上海证券 报、长春新区管委会联合主办的"创新转型，'吉'聚动能"——2025长春新材料与医药行业交流会举行。 国内外上市公司高管、金融投资机构负责人、院校专家及行业协会代表等百余位嘉宾齐聚长春，通过实 地考察与深度座谈，共探合作新机遇，共谋发展新路径。 北国春城 "吉"聚动能 ——多方联动共探长春新材料与医药产业发展新机遇 为进一步促进产业交流与合作，此次活动安排了实地考察与专题交流环节。9月19日下午，与会嘉宾先 后走进长春新质生产力促进中心、长光卫星技术股份有限公司和长春新区规划展览馆，通过现场观摩与 交流，深入了解长春新区在培育新质生产力、推动科技创新与产业升级等方面的创新实践与发展潜力。 "老工业基地焕发的创新活力令人振奋。"多位与会嘉宾表示，从顶层规划到企业实践，从科研突破到产 业转化，长春新区在创新生态、产业集聚和营商环境建设方面的成果令人印象深刻。 在全球科技创新与产业变革加速融合的背景下，新材料与生物医药作为战略性新兴产业，正成为推动经 济高质量发展的重要引擎。吉林作为我国 ...

Core Viewpoint - The company, Boji Pharmaceutical, has received a patent from the National Intellectual Property Administration for a method to measure gallic acid in berberine [2] Group 1 - The patent is titled "A method for determining gallic acid in berberine" [2] - The announcement was made on the evening of September 19 [2]

Core Insights - The company held an investor meeting on September 19, discussing its ongoing projects and financial performance [1][2] - The "Semaglutide Injection" project with Novartis is currently in the Phase III clinical trial follow-up stage, which is expected to positively impact future operating performance [1] - The company focuses on providing CRO services primarily for innovative drugs across various therapeutic areas [1] Group 1: Project Development - The company is developing several innovative drugs, including a traditional Chinese medicine for chronic heart failure and a small molecule new drug for high uric acid levels [2] - Currently, there are no self-developed projects in the oncology field, but the company provides clinical research services for multiple oncology drugs [2] - The timeline for research and development is influenced by project progress and the sponsor's investment [2] Group 2: Financial Management - The company emphasizes improving operational quality as the core of its market value management [2] - Idle cash is primarily invested in low-risk, high-liquidity financial products rather than high-risk securities or derivatives [2] - For the first half of 2025, the company's R&D investment was approximately 23.2 million, accounting for about 6% of revenue, which is higher than the net profit for the same period [2]

Group 1: Company Overview - Boji Pharmaceutical Technology Co., Ltd. primarily operates as a CRO service provider, offering outsourced pharmaceutical research and development services, focusing on innovative drugs across various therapeutic areas [2][4]. - The company has multiple self-developed projects at different research stages, although none have reached the market sales stage yet [4]. Group 2: Clinical Trials and Product Development - The project involving "Semaglutide Injection" is currently in the clinical trial follow-up phase, with the timeline for completion and market application dependent on project progress and client drug approval schedules [3][4]. - Current research projects include traditional Chinese medicine innovative drugs for chronic heart failure and small molecule new drugs for conditions like hyperuricemia and reversible cataracts [4]. Group 3: Financial Performance and Market Position - The company emphasizes improving operational quality as a core aspect of market value management, acknowledging the disparity between its stock price and the performance of innovative drug indices [5]. - For the first half of 2025, the company's R&D expenditure was approximately 2,320,000 yuan, accounting for about 6% of its revenue [6]. Group 4: Investment and Asset Management - The company manages idle funds by investing in safe, liquid, and low-risk financial products, avoiding high-risk investments such as stock trading or derivatives [6].